CellSearch CMMC assay shows analytical sensitivity for non-invasive MRD monitoring in multiple myeloma

A study, for which the design, phase, and population details were not reported, assessed the analytical performance of the CellSearch CMMC assay for non-invasive, longitudinal minimal residual disease monitoring in multiple myeloma. The comparator was standard bone marrow biopsies. The primary outcome was the assay's analytical performance, with key results including a WBC-normalized analytical sensitivity of 2.45 x 10^-7 and a limit of quantitation of 5 cells per run. The assay demonstrated a robust negative predictive value, though specific numerical values for this and other performance metrics were not provided.

Safety and tolerability data were not reported in the available information. The study's key limitations include the absence of reported clinical validation data, patient outcomes, or direct comparative performance data against the gold standard of bone marrow biopsies in a clinical cohort. Details on sample size, study setting, follow-up duration, and funding or conflicts of interest were also not reported.

In terms of practice relevance, the assay is presented as a patient-friendly, non-invasive tool that could potentially serve as a complement to serial bone marrow biopsies, possibly reducing their frequency in appropriate contexts. However, the evidence is limited to analytical performance; its role in clinical decision-making and impact on patient outcomes remain unvalidated. Clinicians should interpret these preliminary analytical findings with caution pending robust clinical studies.